A Randomised Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Palovarotene Ophthalmic Solution
Tóm tắt
Palovarotene, a selective retinoic acid receptor γ agonist, is under investigation for the treatment of dry eye disease. This study aimed to determine the ocular and systemic safety, tolerability and pharmacokinetics of palovarotene ophthalmic solution (PVO-OS) in healthy adults. This was a randomised, vehicle-controlled phase I study (NCT04762355; retrospectively registered). Participants received either PVO-OS (at 0.025, 0.05 or 0.10 mg/mL) or a vehicle (placebo-to-match PVO-OS) once-daily or twice-daily for seven consecutive days. Safety was assessed by ocular and systemic assessments. Blood samples for pharmacokinetic assessments were collected before and after dose administration. Thirty-six participants were randomised to PVO-OS and 12 to the vehicle. Overall, 89 treatment-emergent ocular adverse events (TEOAEs) were reported by 22 participants (61.1%) receiving PVO-OS and ten TEOAEs were reported by five participants (41.7%) receiving the vehicle. Erythema, irritation and skin dryness of the eyelid were the most common TEOAEs in participants receiving PVO-OS. The incidence of TEOAEs and eyelid-related findings in the PVO-OS groups increased with ascending dose and frequency compared with participants treated with the vehicle. All TEOAEs were mild (96.6%) or moderate (3.4%) and resolved without sequelae. Plasma palovarotene concentrations were generally measurable for up to 3–4 h for 0.025 mg/mL and 0.05 mg/mL and up to 12 h for 0.10 mg/mL dose regimens, independent of the frequency of administration. PVO-OS was generally well tolerated at doses up to and including 0.10 mg/mL twice daily. Similar pharmacokinetic profiles were observed for the once-daily and twice-daily regimens following multiple ascending doses of PVO-OS.
Tài liệu tham khảo
Nelson JD, Craig JP, Akpek EK, Azar DT, Belmonte C, Bron AJ, et al. TFOS DEWS II Introduction Ocul Surf. 2017;15:269–75.
The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:93–107. https://pubmed.ncbi.nlm.nih.gov/17508117/.
Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112:71–82.
Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:163–78. https://pubmed.ncbi.nlm.nih.gov/17508120/.
Javadi M-A, Feizi S. Dry eye syndrome. J Ophthalmic Vis Res. 2011;6:192–8.
O’Neil EC, Henderson M, Massaro-Giordano M, Bunya VY. Advances in dry eye disease treatment. Curr Opin Ophthalmol. 2019;30:166–78.
Novack GD. Repurposing medications. Ocul Surf. 2020;19:336–40.
Haber SL, Benson V, Buckway CJ, Gonzales JM, Romanet D, Scholes B. Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol. 2019;11:2515841419870366.
Baudouin C, Irkeç M, Messmer EM, Benítez-del-Castillo JM, Bonini S, Figueiredo FC, ODISSEY European Consensus Group Members, et al. Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting. Acta Ophthalmol. 2018;96:111–9.
Taylor M, Ousler G, Torkildsen G, Walshe C, Fyfe MCT, Rowley A, et al. A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease. Clin Ophthalmol. 2019;13:261–75.
White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. Treatment satisfaction among patients using anti-inflammatory topical medications for dry eye disease. Clin Ophthalmol. 2020;14:875–83.
Nezzar H, Chiambaretta F, Marceau G, Blanchon L, Faye B, Dechelotte P, Rigal D, Sapin V. Molecular and metabolic retinoid pathways in the human ocular surface. Mol Vis. 2007;13:1641–50.
Milner MS, Beckman KA, Luchs JI, Allen QB, Awdeh RM, Berdahl J, et al. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders: new strategies for diagnosis and treatment. Curr Opin Ophthalmol. 2017;27(Suppl. 1):3–47.
Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol. 2009;147:206-13.e203.
Kobayashi TK, Tsubota K, Takamura E, Sawa M, Ohashi Y, Usui M. Effect of retinol palmitate as a treatment for dry eye: a cytological evaluation. Ophthalmologica. 1997;211:358–61.
Selek H, Unlü N, Orhan M, Irkeç M. Evaluation of retinoic acid ophthalmic emulsion in dry eye. Eur J Ophthalmol. 2000;10:121–7.
Tseng SC, Maumenee AE, Stark WJ, Maumenee IH, Jensen AD, Green WR, et al. Topical retinoid treatment for various dry-eye disorders. Ophthalmology. 1985;92:717–27.
Kimura K, Orita T, Liu Y, Yang Y, Tokuda K, Kurakazu T, et al. Attenuation of EMT in RPE cells and subretinal fibrosis by an RAR-γ agonist. J Mol Med. 2015;93:749–58.
Liu Y, Kimura K, Orita T, Suzuki K, Teranishi S, Mori T, Sonoda K-H. Inhibition by a retinoic acid receptor γ agonist of extracellular matrix remodeling mediated by human Tenon fibroblasts. Curr Opin Ophthalmol. 2015;21:1368–77.
Beck RW, Maguire MG, Bressler NM, Glassman AR, Lindblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. 2007;114:1804–9.
Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017;15:539–74.
White DE, Zhao Y, Ogundele A, Fulcher N, Acs A, Moore-Schiltz L, et al. Real-world treatment patterns of cyclosporine ophthalmic emulsion and Lifitegrast ophthalmic solution among patients with dry eye. Clin Ophthalmol. 2019;13:2285–92.
Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15:802–12.
Cursiefen C, Cordeiro F, Cunha-Vaz J, Wheeler-Schilling T, Scholl HPN. Unmet needs in ophthalmology: a European Vision Institute-Consensus Roadmap 2019–2025. Ophthalmic Res. 2019;62:123–33.
Dunn JD, Karpecki PM, Meske ME, Reissman D. Evolving knowledge of the unmet needs in dry eye disease. Am J Manag Care. 2021;27:S23-32.
Baudouin C, Messmer EM, Aragona P, Geerling G, Akova YA, Benítez-del-Castillo J, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100:300–6.
Mills CM, Marks R. Adverse reactions to oral retinoids. Drug Saf. 1993;9:280–90.
Desai A, Kartono F, Del Rosso JQ. Systemic retinoid therapy: a status report on optimal use and safety of long-term therapy. Dermatol Clin. 2007;25:185–93.
Bell ML, Whitehead AL, Julious SA. Guidance for using pilot studies to inform the design of intervention trials with continuous outcomes. Clin Epidemiol. 2018;10:153–7.
Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318–26.